Cost-utility analyses of clinical preventive services. Published ratios, 1976-1997

American Journal of Preventive Medicine

Volumn 19, Issue 1, 2000, Pages 15-23

  Stone, Patricia W ^a   Teutsch, Steven ^b   Chapman, Richard H ^c   Bell, Chaim ^c   Goldie, Sue J ^c   Neumann, Peter J ^c  

^a UNIVERSITY OF ROCHESTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHEMOPROPHYLAXIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HUMAN; IMMUNIZATION; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR;

COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION; MASS SCREENING; PREVENTIVE HEALTH SERVICES; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 0034129982     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-3797(00)00151-3     Document Type: Article

References (92)

1. Guide to clinical preventive services. 2nd ed. 1996;Williams & Wilkins, Baltimore.
2. Messonnier ML, Corso PS, Teutsch SM, Haddix AC, Harris JR. An ounce of prevention ... what are the returns? Am J Prev Med 1999;16(3):248-63.
3. An ounce of prevention ... what are the returns? 2nd ed. 1999;U.S. Department of Health and Human Services, Washington, DC.
4. Phillips K.A., Holtgrave D.R. Using cost-effectiveness/cost-benefit analysis to allocate health resources a level playing field for prevention? Am J Prev Med. 13:1997;18-25.
5. Ganiats T.G. Prevention, policy, and paradox what is the value of future health? Am J Prev Med. 13:1997;12-17.
6. Teutsch S.M. A framework for assessing the effectiveness of disease and injury prevention. MMWR. 41:1992;1-13.
7. Wang L.I., Haddix A.C., Teutsch S.M., Caldwell B. The role of resource allocation models in selecting clinical preventive services. Am J Managed Care. 5:1999;445-454.
8. Gold M.R., Siegel J.E., Russell L.B., Weinstein M.C. Cost-effectiveness in health and medicine. 1996;Oxford University Press, New York.
9. Russell L.B., Gold M.R., Siegel J.E., Daniels N., Weinstein M.C. The role of cost-effectiveness analysis in health and medicine. JAMA. 276:1996;1172-1177.
10. Siegel J.E., Weinstein M.C., Russell L.B., Gold M.R. Recommendations for reporting cost-effectiveness analyses. JAMA. 276:1996;1339-1341.
11. Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., Russell L.B. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 276:1996;1253-1258.
12. Mason J.M. Cost-per-QALY league tables their role in pharmacoeconomic analysis . Pharmaco Economics. 5:1994;472-481.
13. Drummond M., Torrance G., Mason J. Cost-effectiveness league tables more harm than good? Soc Sci Med. 37:1993;33-40.
14. Balas E.A., Kretschmer R.A., Gnann W., et al. Interpreting cost analyses of clinical interventions. JAMA. 279:1998;54-57.
15. Drummond M.F. Survey of cost-effectiveness and cost-benefit analyses in industrialized countries. World Health Stat Q. 38:1985;383-401.
16. Ganiats T.G., Wong A.F. Evaluation of cost-effectiveness research a survey of recent publications . Fam Med. 23:1991;457-462.
17. Gerard K. Cost-utility in practice a policy maker's guide to the state of the art . Health Policy. 21:1992;249-279.
18. Gerard K., Smoker I., Seymour J. Raising the quality of cost-utility analyses lessons learnt and still to learn . Health Policy. 46:1999;217-238.
19. Graham J.D., Corso P.S., Morris J.M., Segui-Gomez M., Weinstein M.C. Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health. 19:1998;125-152.
20. Hornberger J.C., Redelmeier D.A., Petersen J. Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol. 45:1992;505-512.
21. Jacobs P., Fassbender K. The measurement of indirect costs in the health economics evaluation literature a review . Int J Technol Assess Health Care. 14:1998;799-808.
22. Neumann P.F., Zinner D.E., Wright J.C. Are methods for estimating QALYS in cost-effectiveness analyses improving? Med Decis Making. 17:1997;402-408.
23. Neumann PJ, Stone PW, Chapman RH, Sandberg E, Bell C. A formal audit of 228 cost-utility analyses. Working Paper, Harvard School of Public Health, 1999.
24. Stone PW, Chapman RH, Sandberg E, Liljas B, Neumann PJ. Measuring costs in cost-utility analyses: variations in the literature. Int J Technol Assess Health Care (in press).
25. Tengs T.O., Adams M.E., Pliskin J.S., et al. Five hundred life-saving interventions and their cost-effectiveness. Risk Anal. 3:1995;369-390.
26. Drummond M.F., Richardson W.S., O'Brien B.J., Levine M., Heyland D. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? JAMA. 277:1997;1552-1557.
27. Luce B., Simpson K. Methods in cost-effectiveness analysis areas of concern and debate . Clin Ther. 17:1995;109.
28. O'Brien B., Heyland D., Richardson W.S., et al. How to use an article on economic analysis of clinical practice. B. What are the results and will they help me in caring for my patients? JAMA. 277:1997;1802-1806.
29. Chapman RH, Stone PW, Sandberg E, Neumann PJ. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies. Med Decis Making (in press).
30. Bureau of Labor Statistics. Consumer price index - all urban consumers, series ID: CUUR0000SAO. Available at: http://146.142.4.24/cgi-bin/surveymost?bls. Accessed March 17, 1999.
31. Willems J.S., Sanders C.R., Riddiough M.A., Bell J.C. Cost-effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med. 303:1980;553-559.
32. Sisk J.E., Moskowitz A.J., Whang W., et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA. 278:1997;1333-1339.
33. Harris A., Hendrie D., Bower C., Payne J., de Klerk N., Stanley F. The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP. Med J Aust. 160:1994;483-488.
34. McIntyre P., Hall J., Leeder S. An economic analysis of alternatives for childhood immunisation against Haemophilus influenzae type b disease. Aust J Public Health. 18:1994;394-400.
35. Livartowski A., Boucher J., Detournay B., Reinert P. Cost-effectiveness evaluation of vaccination against Haemophilus influenzae invasive diseases in France. Vaccine. 14:1996;495-500.
36. Mangtani P., Hall A.J., Normand C.E. Hepatitis B vaccination the cost effectiveness of alternative strategies in England and Wales . J Epidemiol Community Health. 49:1995;238-244.
37. Smith S., Weber S., Wiblin T., Nettleman M. Cost-effectiveness of hepatitis A vaccination in health care workers. Infect Contr Hosp Epidemiol. 18:1997;688-691.
38. Shepard D.S., Walsh J.A., Kleinau E., Stansfield S., Bhalotra S. Setting priorities for the Children's Vaccine Initiative a cost-effectiveness approach . Vaccine. 13:1995;707-714.
39. Pinkerton S.D., Holtgrave D.R., Pinkerton H.J. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV. Arch Intern Med. 177:1997;1972-1980.
40. Rose D.N., Schechter C.B., Silver A., Fahs M.C. Cost effectiveness of isoniazid chemoprophylaxis. Goldbloom R.B., Lawrence R.S. Preventing disease beyond the Rhetoric. The cost effectiveness of preventive services: some examples . 1990;446-449 Springer-Verlag, New York.
41. Tsevat J., Durand-Zaleski I., Pauker S.G. Cost-effectiveness of antibiotic prophylaxis for dental procedures in patients with artificial joints. Am J Pub Health. 79:1989;739-743.
42. Jacobson J.J., Schweitzer S.O., Kowalski C.J. Chemoprophylaxis of prosthetic joint patients during dental treatment a decision-utility analysis . Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 72:1991;167-177.
43. Weinstein M.C. Estrogen use in postmenopausal women - costs, risks, and benefits. N Engl J Med. 303:1980;308-316.
44. Tosteson A.N., Rosenthal D.I., Melton L.J., Weinstein M.C. Cost-effectiveness of screening perimenopausal white women for osteoporosis bone densitometry and hormone replacement therapy . Ann Intern Med. 113:1990;594-603.
45. Weinstein M.C., Tosteson A.N. Cost-effectiveness of hormone replacement multidisciplinary perspective on menopause . Ann N Y Acad Sci. 592:1990;162-172.
46. Cheung A.P., Wren B.G. A cost-effectiveness analysis of hormone replacement therapy in the menopause. Med J Aust. 156:1992;312-316.
47. Geelhoed E., Harris A., Prince R. Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture. Aust J Public Health. 18:1994;153-160.
48. Fiscella K., Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA. 275:1996;1247-1251.
49. Littenberg B., Garber A.M., Sox H.C. Jr. Screening for hypertension. Ann Intern Med. 112:1990;192-202.
50. Russell J.G. Is screening for abdominal aortic aneurysm worthwhile? Clin Radiol. 41:1990;182-184.
51. Derdeyn C.P., Powers W.J. Cost-effectiveness of screening for asymptomatic carotid atherosclerotic disease. Stroke. 27:1996;1944-1950.
52. St Leger A.S., Spencely M., McColloum C.N., Mossa M. Screening for abdominal aortic aneurysm a computer assisted cost-utility analysis . Eur J Vasc Endovasc Surg. 11:1996;183-190.
53. Lee T.T., Solomon N.A., Heidenreich P.A., Oehlert J., Garber A.M. Cost-effectiveness of screening for carotid stenosis in asymptomatic patients. Ann Intern Med. 126:1997;337-346.
54. Nissinen A., Tuomilehto J., Kottke T.E., Puska P. Cost-effectiveness of the North Karelia Hypertension Program 1972-1977 . Med Care. 24:1986;767-780.
55. de Koning H.J., van Ineveld B.M., van Oortmarssen G.J., et al. Breast cancer screening and cost-effectiveness policy alternatives, quality of life considerations and the possible impact of uncertain factors . Int J Cancer. 49:1991;531-537.
56. Boer R., de Koning H.J., van Oortmarssen G.J., van der Maas P.J. In search of the best upper age limit for breast cancer screening. Eur J Cancer. 31A:1995;2040-2043.
57. Hall J., Gerard K., Salkeld G., Richardson J. A cost-utility analysis of mammography screening in Australia. Soc Sci Med. 34:1992;993-1004.
58. Krahn M.D., Mahoney J.E., Eckman M.H., Trachtenberg J., Paulker S.G., Detsky A. Screening for prostate cancer a decision analytic view . JAMA. 272:1994;773-780.
59. Hristova L., Hakama M. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017. Acta Oncol. 36:(suppl 9):1997;1-60.
60. Fahs M.C., Mandelblatt J.S. Cost-effectiveness of cervical cancer screening among elderly low-income women. Goldbloom R.B., Lawrence R.S. Preventing disease beyond the Rhetoric. The cost effectiveness of preventive services: some examples . 1990;441-446 Springer-Verlag, New York.
61. Anderson J.P., Moser R.J. Parasite screening and treatment among Indochinese refugees cost-benefit/utility and the General Health Policy Model . JAMA. 253:1985;2229-2235.
62. Schechter C.B., Rose D.N., Fahs M.C., Silver A.L. Tuberculin screening cost-effectiveness analysis of various testing schedules . Am J Prev Med. 6:1990;167-175.
63. Nolan J.P., Tarsa N.J., DiBenedetto G. Case-finding for unsuspected thyroid disease costs and health benefits . Am J Clin Pathol. 83:1985;346-355.
64. Danese M.D., Powe N.R., Sawin C.T., Ladenson P.W. Screening for mild thyroid failure at the periodic health examination. JAMA. 276:1996;285-292.
65. Adams P.C., Kertesz A.E., Valberg L.S. Screening for hemochromatosis in children of homozygotes prevalence and cost-effectiveness . Hepatol. 22:1995;1720-1727.
66. Adams P.C., Gregor J.C., Kertesz A.E., Valberg L.S. Screening blood donors for hereditary hemochromatosis decision analysis model based on a 30-year database . Gastroenterol. 109:1995;177-188.
67. Holtgrave D.R., Kelly J.A. Preventing HIV/AIDS among high-risk urban women the cost-effectiveness of a behavioral group intervention . Am J Public Health. 86:1996;1442-1445.
68. Pinkerton S.D., Holtgrave D.R., Valdisseri R.O. Cost-effectiveness of HIV-prevention skills training for men who have sex with men. AIDS. 11:1997;347-357.
69. Hatziandreu E.I., Koplan J.P., Weinstein M.C., Caspersen C.J., Warner K.E. A cost-effective analysis of exercise as a health promotion activity. Am J Public Health. 78:1988;1417-1421.
70. Salkeld G., Phongsavan P., Oldenburg B., et al. The cost-effectiveness of a cardiovascular risk reduction program in general practice. Health Policy. 41:1997;105-119.
71. Zeckhauser R., Shepard D. Where now for saving lives. Law Contemporary Problems. 40:1976;4-45.
72. Busch M.P., Korelitz J.J., Kleinman S.H., AuBuchon J.P., Schreiber G.B. The Retrovirus Epidemiology Donor Study declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection . Transfusion. 35:1995;903-910.
73. AuBuchon J.P., Birkmeyer J.D., Busch M.P. Cost-effectiveness of expanded human immunodeficiency virus testing protocols for donated blood. Transfusion. 37:1997;45-51.
74. Birkmeyer J.D., Goodnough L.T., AuBuchon J.P., Littenberg B. The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion. 33:1993;544-551.
75. Birkmeyer J.D., AuBuchon J.P., Littenberg B., et al. Cost-effectiveness of preoperative autologous donation in coronary artery bypass grafting. Ann Thorac Surg. 57:1994;161-168.
76. Goodnough L.M., Grishaber J.E., Birkmeyer J.D., Monk T.G., Catalona W.J. Efficacy and cost-effectiveness of autologous blood predeposit in patients undergoing radical prostatectomy procedures. Urology. 44:1994;226-231.
77. Etchason J., Petz L., Keeler E., Calhoun L., Kleinman S., Snider C. The cost-effectiveness of preoperative autologous blood donations. N Engl J Med. 332:1995;719-724.
78. Huber T.S., McGorray S.P., Carlton L.C., Irwin P.B., Flug R.R., Flynn T.C. Intraoperative autologous transfusion during elective infrarenal aortic reconstruction a decision analysis model . J Vasc Surg. 25:1997;984-994.
79. AuBuchon J.P., Birkmeyer J.D. Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of zero-risk blood supply. JAMA. 272:1994;1210-1214.
80. Lawler F.H., Bisonni B.S., Holtgrave D.R. Circumcision A decision analysis of its medical value . Fam Med. 23:1991;587-593.
81. Cromwell J., Bartosch W.J., Fiore M.C., Hasselblad V., Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA. 278:1997;1759-1766.
82. Wright J.C., Weinstein M.C. Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl J Med. 339:1998;380-386.
83. Carande-Kulis VG, Maciosek MV, Briss PA, et al. Methods for systematic reviews of economic evaluations for the Guide to Community Preventive Services. Am J Prev Med 2000;19:xxx-xxx.
84. Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs measurement through quality of life? A response to the recommendation of the Washington panel. Health Econ 1997;6:253-9.
85. Brouwer W.B., Koopmanschap M.A., Rutten F.F. Productivity costs in cost-effectiveness analysis numerator or denominator. A further discussion . Health Econ. 6:1997;511-514.
86. Weinstein M.C., Siegel J.E., Garber A.M., et al. Productivity costs, time costs and health-related quality of life a response to the Erasmus group . Health Econ. 6:1997;505-510.
87. Baladi J, Menon D, Otten N. Uses of economic evaluation guidelines: 2 years' experience in Canada. Health Econ 1998;7:221-27.
88. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals. 2nd ed. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997.
89. Commonwealth Department of Human Services and Health. Australian guidelines. Canberra: Australian Government Publishing Service, 1995.
90. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83.
91. Drummond M.F., O'Brien B., Stoddart G.L., Torrance G.W. Methods for the economic evaluation of health care programmes. 2nd ed. 1997;Oxford University Press, New York.
92. Jefferson T., Smith R., Yee Y., et al. Evaluating the BMJ guidelines for economic submissions prospective audit of economic submissions to BMJ and The Lancet . JAMA. 280:1998;275-277.